Cargando…

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is the most common driver in NSCLC, and targeting oncogenic KRAS is a major challenge in the treatment of non-small-cell lung cancer (NSCLC). While several covalent KRAS G12C inhibitors have emerged as a novel anti-KRAS therapy, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sunaga, Noriaki, Miura, Yosuke, Kasahara, Norimitsu, Sakurai, Reiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656763/ https://www.ncbi.nlm.nih.gov/pubmed/34885068 http://dx.doi.org/10.3390/cancers13235956

Ejemplares similares

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
por: Miura, Yosuke, et al.
Publicado: (2018)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga, Noriaki, et al.
Publicado: (2015)

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
por: Román, Marta, et al.
Publicado: (2018)

KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
por: Chen, Hanxiao, et al.
Publicado: (2020)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis
por: Sunaga, Noriaki, et al.
Publicado: (2022)

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
por: Kasahara, Norimitsu, et al.
Publicado: (2020)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles
por: Yang, Linlin, et al.
Publicado: (2023)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
por: Reita, Damien, et al.
Publicado: (2022)

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
por: Shin, Dong Hoon, et al.
Publicado: (2023)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
por: O’Sullivan, Éabha, et al.
Publicado: (2023)

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
por: Listì, Angela, et al.
Publicado: (2019)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
por: Guo, Yijia, et al.
Publicado: (2019)

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations
por: Kanbe, Mio, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
por: Shu, Chun-Lu, et al.
Publicado: (2022)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
por: De Carlo, Elisa, et al.
Publicado: (2022)

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
por: Ceddia, Serena, et al.
Publicado: (2022)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Kras as a key oncogene and therapeutic target in pancreatic cancer
por: Collins, Meredith A., et al.
Publicado: (2014)

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer
por: Kamerkar, Sushrut, et al.
Publicado: (2017)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non–small-cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2019)

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
por: Calabrese, Fiorella, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_76omd541tv7ara7nfgk17t4vmq